Generic Oncology Sterile Injectable Market Report 2025

The generic oncology sterile injectable market size has grown rapidly in recent years. It will grow from $17.17 billion in 2024 to $19.13 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to patent expirations for branded oncology drugs, increasing prevalence of cancer, growing focus on cost-effective healthcare solutions, regulatory support for generic medications, expansion of generic pharmaceutical companies.

The generic oncology sterile injectable market size is expected to see rapid growth in the next few years. It will grow to $30.17 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing healthcare investments, adoption of biosimilars in oncology, expansion of oncology drug pipelines, rise in global cancer incidence, regulatory pathways for generic sterile injectables. Major trends in the forecast period include development of complex generic oncology drugs, increasing use of advanced manufacturing technologies, rise of personalized medicine in oncology, growing emphasis on biosimilar competition, integration of digital technologies in supply chain management.

The increasing prevalence of cancer is projected to drive the growth of the generic oncology sterile injectable market in the coming years. Cancer encompasses a range of diseases that can arise in any organ or tissue when abnormal cells multiply uncontrollably, exceed their normal limits, and potentially spread to other organs or invade adjacent body parts. The rise in cancer cases is fueled by factors such as smoking, radiation exposure, carcinogens, obesity, and genetic mutations. Generic oncology sterile injectable products are utilized to reduce tumors and inhibit the growth of cancer cells. For example, in April 2024, the International Agency for Research on Cancer, a France-based research organization, reported nearly 20 million new cancer cases and almost 10 million cancer-related deaths in 2022. Projections suggest that the annual number of new cases could reach 35 million by 2050, marking a 77% increase from 2022. Therefore, the rising prevalence of cancer is significantly driving the growth of the oncology sterile injectable market.

The rising government investments in oncology services are expected to boost the growth of the generic oncology sterile injectable market in the future. Government investments refer to the allocation of public funds by authorities toward various projects, programs, and initiatives to achieve specific economic, social, or strategic goals. Enhanced government funding for cancer research, treatment facilities, and healthcare infrastructure improves the accessibility and quality of oncology services. For instance, in September 2024, Cancer Research UK, a cancer research organization based in the UK, allocated £399 million for the 2023/24 financial year. This funding included £93 million for research across all cancer types and £84 million for basic research aimed at understanding the fundamental biology of cancer. Therefore, increasing government investments in oncology services are significantly driving the growth of the oncology sterile injectable market.

Product innovation is a prominent trend gaining traction in the generic oncology sterile injectable market. Leading companies in the sector are actively involved in developing innovative products to maintain their competitive edge. For example, in July 2022, Dr. Reddy's Laboratories, an India-based pharmaceutical company, introduced Bortezomib for injection, a generic version of Velcade. This injection, available in a single-dose vial with a dosage of 3.5 mg per 10 mL, is designed for intravenous or subcutaneous administration and is utilized in cancer treatment.

Leading companies in the generic oncology sterile injectable market are focusing on developing innovative medications, such as ready-to-use injectable (RTU) anti-nausea treatments, to improve patient care and enhance treatment outcomes. RTU anti-nausea treatments provide rapid relief from nausea, which helps enhance patients' overall treatment experiences and promotes adherence to chemotherapy regimens. For example, in September 2024, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, launched focinveztm (fosaprepitant), a ready-to-use injectable aimed at preventing acute and delayed nausea and vomiting in adults and pediatric patients aged six months and older undergoing highly and moderately emetogenic chemotherapy. This product is free of Polysorbate 80 and requires no reconstitution or dilution, allowing for direct administration from its single-dose vial. This innovation is significant for the generic oncology sterile injectable market, as it provides a differentiated treatment option that improves pharmacy efficiency and includes a unique reimbursement code for chemotherapy patients.

In April 2022, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, completed the acquisition of Custopharm Inc. for $425 million. This strategic move is anticipated to enhance Hikma Pharmaceuticals' injectables business by incorporating a compelling portfolio of marketed products. Custopharm Inc. is a US-based company specializing in generic sterile injectables.

Major companies operating in the generic oncology sterile injectable market include Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Sun Pharmaceutical Industries Inc., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Zydus Lifesciences Limited, Nichi-Iko Pharmaceutical Co. Ltd., Biocon Ltd., Jubilant Pharmova Ltd., Gland Pharma Limited, Apotex Inc., Accord Healthcare Ltd.

North America was the largest region in the generic oncology sterile injectable market in 2024. Asia-Pacific is expected to be the generic oncology sterile injectable market report during the fastest-growing region in the forecast period. The regions covered in the generic oncology sterile injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the generic oncology sterile injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A generic oncology sterile injectable is a biologic drug containing the same active ingredients as the branded version but differing only in the inactive components. It is utilized in the treatment of various cancer types, including breast, prostate, and colorectal cancers.

The primary products within the category of generic oncology sterile injectables include chemotherapy, antimetabolites, plant alkaloids, antitumor antibiotics, and other related medications. Chemotherapy, a type of treatment that employs potent chemicals to eliminate rapidly dividing cells in the body, is among the key components. These drugs are made available through diverse distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies. They are employed in the treatment of ovarian cancer, breast cancer, lung cancer, pancreatic cancer, and various other malignancies.

The generic oncology sterile injectable research report is one of a series of new reports that provides generic oncology sterile injectable market statistics, including the generic oncology sterile injectable industry's global market size, regional shares, competitors with generic oncology sterile injectable market share, detailed generic oncology sterile injectable market segments, market trends and opportunities, and any further data you may need to thrive in the generic oncology sterile injectable industry. This generic oncology sterile injectable market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The generic oncology sterile injectable market consists of sales of paclitaxel injection, doxorubicin hydrochloride injection, and gemcitabine hydrochloride injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.